Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP9 | Q86TI2 | 15/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 14/20 | 0.46 |
| ▸ | GLMN | Q92990 | 3/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6510576 | 0.93 | DPP4 (0.52) | DPP9DPP8GLMNCNR2DPP4 | |
| SCHEMBL6498258 | 0.83 | TSHR (0.46) | CNR2DPP4ALDH1A1HSD11B1 | |
| SCHEMBL6507760 | 0.83 | TSHR (0.46) | CNR2DPP4ALDH1A1HSD11B1 | |
| SCHEMBL6500416 | 0.80 | EPHX2 (0.37) | DPP4ALDH1A1 | |
| SCHEMBL6506039 | 0.80 | MAPT (0.36) | CNR2DPP4ALDH1A1 | |
| SCHEMBL6428167 | 0.77 | HSP90AA1 (0.39) | DPP9DPP8GLMNALDH1A1 | |
| SCHEMBL6502963 | 0.77 | DPP9 (0.37) | DPP9DPP8GLMNALDH1A1 | |
| SCHEMBL6426530 | 0.75 | P2RX7 (0.35) | CNR2 | |
| SCHEMBL6507694 | 0.74 | ALDH1A1 (0.46) | DPP9DPP8DPP4ALDH1A1 | |
| SCHEMBL6427319 | 0.74 | CNR2 (0.50) | CNR2ALDH1A1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | DPP9 1066/4885DPP8 1825/4885GLMN 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.